Article
Oncology
Jianyong Zhuo, Di Lu, Jianguo Wang, Zhengxing Lian, Jiali Zhang, Huihui Li, Beini Cen, Xuyong Wei, Qiang Wei, Haiyang Xie, Xiao Xu
Summary: The successful engraftment of HCC PDXs was significantly related to molecular features, with GPC3(+)/Ki67(+) phenotype tumors being the most likely to successfully establish HCC PDXs.
CHINESE JOURNAL OF CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Akio Miyasaka, Yuichi Yoshida, Akiko Suzuki, Kei Sawara, Yasuhiro Takikawa
Summary: This study investigated the long-term incidence of HCC after achieving SVR with DAA treatment for HCV, finding that Fib-4 index and previous HCC history were independent predictors for the development of HCC post-treatment. A novel scoring system based on these factors was established to identify patients at higher risk for HCC occurrence. Patients with these risk factors should be closely monitored.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Amy K. Kim, James P. Hamilton, Selena Y. Lin, Ting-Tsung Chang, Hie-Won Hann, Chi-Tan Hu, Yue Lou, Yih-Jyh Lin, Terence P. Gade, Grace Park, Harry Luu, Tai-Jung Lee, Jeremy Wang, Dion Chen, Michael G. Goggins, Surbhi Jain, Wei Song, Ying-Hsiu Su
Summary: The study found that urine circulating tumor DNA can be used as a potential screening test for hepatocellular carcinoma, especially in patients with low serum AFP levels, and it can improve the detection rate of early-stage HCC.
BRITISH JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Sean A. Woolen, Amit G. Singal, Matthew S. Davenport, Jonathan P. Troost, Shokoufeh Khalatbari, Sukul Mittal, Sehar Siddiqui, Austin Fobar, Jason Morris, Mobolaji Odewole, Elliot B. Tapper, Anjana Pillai, Neehar D. Parikh
Summary: This study assessed patients with cirrhosis' preferences for HCC surveillance modalities, finding that patients prioritize benefits of surveillance over potential harms or inconveniences. Patients showed a preference for abbreviated MRI, MRI, or blood-based biomarkers over traditional ultrasound or ultrasound with AFP.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Oncology
Weronika Pioronska, Zeribe Chike Nwosu, Mei Han, Michael Buettner, Matthias Philip Ebert, Steven Dooley, Christoph Meyer
Summary: PRRX1 is frequently upregulated in human HCC and predicted to be directly correlated with focal adhesion and epithelial-mesenchymal transition. High expression of PRRX1, low ZEB1, or high ZEB2 can significantly predict better overall survival in HCC patients. Silencing of PRRX1 accelerates proliferation and clonogenicity in HCC cell lines.
Article
Oncology
Gadi Lalazar, David Requena, Lavoisier Ramos-Espiritu, Denise Ng, Patrick D. Bhola, Ype P. de Jong, Ruisi Wang, Nicole J. C. Narayan, Bassem Shebl, Solomon Levin, Eleftherios Michailidis, Mohammad Kabbani, Koen O. A. Vercauteren, Arlene M. Hurley, Benjamin A. Farber, William J. Hammond, James A. Saltsman, Ethan M. Weinberg, J. Fraser Glickman, Barbara A. Lyons, Jessica Ellison, Erik Schadde, Martin Hertl, Jennifer L. Leiting, Mark J. Truty, Rory L. Smoot, Faith Tierney, Tomoaki Kato, Hans-Guido Wendel, Michael P. LaQuaglia, Charles M. Rice, Anthony Letai, Philip Coffino, Michael S. Torbenson, Michael Ortiz, Sanford M. Simon
Summary: Therapeutics informed by genomics have not been effective for fibrolamellar carcinoma (FLC). A functional drug screen identified that inhibitors of TOPO1 and HDAC, along with napabucasin, showed efficacy on patient-derived xenografts (PDX) of FLC. Inhibiting Bcl-xL in combination with these drugs also showed synergy in treating FLC.
Article
Biochemistry & Molecular Biology
Benjamin Buchard, Camille Teilhet, Natali Abeywickrama Samarakoon, Sylvie Massoulier, Juliette Joubert-Zakeyh, Corinne Blouin, Christelle Reynes, Robert Sabatier, Anne-Sophie Biesse-Martin, Marie-Paule Vasson, Armando Abergel, Aicha Demidem
Summary: This study identified two metabolic phenotypes of HCC developed in NAFLD based on fibrosis level. HCC-F0F1 showed overexpression of choline derivatives and glutamine, while HCC-F3F4 were characterized by decreased monounsaturated fatty acids, increased saturated fatty acids, and accumulation of branched amino acids. Specific signatures such as differential expression levels of glucose, choline derivatives, phosphoethanolamine, monounsaturated fatty acids, and triacylglycerides were found when comparing HCC-F0F1 and HCC-F3F4.
Article
Oncology
Tingbo Ye, Leilei Lin, Lulu Cao, Weiguo Huang, Shengzhe Wei, Yunfeng Shan, Zhongjing Zhang
Summary: Hepatocellular carcinoma patients with abnormal metabolism have worse prognosis. By studying metabolism-related pathways, the researchers classified hepatocellular carcinoma into two clusters and found that patients in one cluster had lower survival rates. They also developed a risk score model based on 11 differentially expressed metabolic genes, which accurately predicted overall survival in hepatocellular carcinoma patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Zili Zhen, Zhemin Shen, Yanmei Hu, Peilong Sun
Summary: A novel signature consisting of 7 angiogenesis-related genes was established to predict the prognosis of HCC patients. Patients in the high-risk group had a poor prognosis, and the risk score was an independent predictor for overall survival. Functional enrichment analysis showed that these genes were enriched in pathways related to cell proliferation and mitosis, with significant differences in immune cell infiltration between the two risk groups.
Article
Genetics & Heredity
Yu Li, Chunyan Wu, Yingnan Ge, Xi Chen, Li Zhu, Ling Chu, Jia Wang, Meiling Yan, Hao Deng
Summary: Using a bioinformatics approach, 11 prognosis-related nucleotide metabolism genes were identified in hepatocellular carcinoma. A prognostic model containing six genes was constructed and found to accurately predict patient prognosis. The risk score generated from the model can be used as an independent prognostic factor and guide chemotherapy drug selection, as well as early patient care.
FRONTIERS IN GENETICS
(2023)
Article
Biochemistry & Molecular Biology
Hongsheng Lin, Yangyi Xie, Yinzhi Kong, Li Yang, Mingfen Li
Summary: This study identified 18 HCC-specific dysregulated immune lncRNAs and two HCC molecular subtypes with significant prognostic differences and immune characteristics. Functional enrichment analysis indicated that the 18 dysregulated immune lncRNAs were enriched in cytokines, cytokine receptors, TGFb family members, TNF family members, and TNF family member receptor pathways. Immunological profiling showed that subtype 1 samples with higher levels of cytokine response had a better survival, but subtype 2 samples with higher levels of tumor proliferation had poorer survival. The current findings help understand the function of lncRNAs and promote the identification of immunotherapy targets.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Gastroenterology & Hepatology
Duaa S. Nasereldin, Launia J. White, David O. Hodge, Lewis R. Roberts, Tushar Patel, Samuel O. Antwi
Summary: The association between obesity and HCC risk is mainly observed in individuals with metabolic abnormalities, while there is no significant association in metabolically healthy individuals.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Pharmacology & Pharmacy
Khoa Nguyen, Katherine Hebert, Emily McConnell, Nicole Cullen, Thomas Cheng, Susanna Awoyode, Elizabeth Martin, Weina Chen, Tong Wu, Suresh K. Alahari, Reza Izadpanah, Bridgette M. Collins-Burow, Sean B. Lee, David H. Drewry, Matthew E. Burow
Summary: The liver is an important organ involved in biological functions such as digestion, nutrient storage, and detoxification. It plays an active role in regulating metabolism and is susceptible to hepatocellular carcinoma, which is often associated with chronic inflammation. LKB1 signaling has been found to regulate cellular metabolism and has a tumor suppressive role in many cancers. Using the KMPlotter database, this review correlates RNA levels of LKB1 signaling genes with hepatocellular carcinoma patient survival outcomes and identifies potential biomarkers for clinical use.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Soudabeh Fazeli, Yesenia Covarrubias, Shirin Bassirian, Jordan Cuevas, Kathryn Fowler, Irine Vodkin, Yuko Kono, Robert Marks, Rohit Loomba, Bachir Taouli, Claude Sirlin, Ruth Carlos
Summary: This study assessed patient preferences for hepatocellular carcinoma screening test attributes and found that higher sensitivity and lower cost were the most important factors influencing patient preferences. Understanding patient preferences for specific screening test characteristics is important for determining adherence.
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
(2022)
Article
Oncology
Zaoqu Liu, Libo Wang, Long Liu, Taoyuan Lu, Dechao Jiao, Yuling Sun, Xinwei Han
Summary: Two heterogeneous ferroptosis subtypes with distinct metabolic and immune characteristics were identified in hepatocellular carcinoma. These subtypes showed differential sensitivity to immunotherapy and sorafenib. Additionally, a reliable risk signature for prognosis and immunotherapy assessment was developed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio Dalla Riva, Edoardo G. Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini, Fabio Farinati
Summary: This study compared patients with MAFLD and non-MAFLD who had hepatocellular carcinoma (HCC) in Italy. It found that the proportion of MAFLD in HCC patients was increasing over time and is expected to surpass non-MAFLD in the future. Despite a later cancer stage at diagnosis, MAFLD HCC patients had a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
Review
Oncology
Burcu Sengez, Brian Carr, Hani Alotaibi
Summary: This article focuses on the association between EMT and inflammation in the context of HCC progression. EMT and inflammation are closely correlated with tumor aggressiveness and poor outcomes, and cellular heterogeneity is a common result. Identifying EMT-related biomarkers and understanding EMT regulatory molecules will contribute to promising developments in clinical practice and can be used for predicting metastasis.
JOURNAL OF GASTROINTESTINAL CANCER
(2023)
Article
Surgery
Veysel Ersan, Sertac Usta, Cemalettin Aydin, Brian Carr, Sinan Karatoprak, Sezai Yilmaz
Summary: This study retrospectively examined the outcomes of non-transplant surgical approaches in patients with Bismuth-Corlette (BC) type IV perihilar cholangiocarcinoma (pCCA). The results showed that patients who underwent hepatectomy and had negative lymph nodes achieved the best survival rates. However, achieving high survival rates remains challenging in this patient population.
ACTA CHIRURGICA BELGICA
(2023)
Article
Medicine, General & Internal
Quirino Lai, Nicoletta De Matthaeis, Michele Finotti, Giovanni Galati, Giuseppe Marrone, Fabio Melandro, Filomena Morisco, Daniele Nicolini, Riccardo Pravisani, Edoardo G. Giannini
Summary: This study evaluates the impact of antiplatelet therapy on the incidence and mortality of hepatocellular carcinoma. The results suggest that antiplatelet therapy is associated with a reduced risk of HCC incidence and post-treatment mortality.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Surgery
Simone Famularo, Matteo Donadon, Federica Cipriani, Federico Fazio, Francesco Ardito, Maurizio Iaria, Pasquale Perri, Simone Conci, Tommaso Dominioni, Quirino Lai, Giuliano La Barba, Stefan Patauner, Sarah Molfino, Paola Germani, Giuseppe Zimmitti, Enrico Pinotti, Matteo Zanello, Luca Fumagalli, Cecilia Ferrari, Maurizio Romano, Antonella Delvecchio, Maria Grazia Valsecchi, Adelmo Antonucci, Fabio Piscaglia, Fabio Farinati, Yoshikuni Kawaguchi, Kiyoshi Hasegawa, Riccardo Memeo, Giacomo Zanus, Guido Griseri, Marco Chiarelli, Elio Jovine, Mauro Zago, Moh'd Abu Hilal, Paola Tarchi, Gian Luca Baiocchi, Antonio Frena, Giorgio Ercolani, Massimo Rossi, Marcello Maestri, Andrea Ruzzenente, Gian Luca Grazi, Raffaele Dalla Valle, Fabrizio Romano, Felice Giuliante, Alessandro Ferrero, Luca Aldrighetti, Davide P. Bernasconi, Guido Torzilli
Summary: This study aimed to create a machine learning predictive model to allocate patients with recurrent hepatocellular carcinoma (HCC) to their best potential treatment based on their specific characteristics. An individualized algorithm for treatment allocation was developed using factors such as age, cirrhosis, number and size of recurrent nodules, extrahepatic spread, and time to recurrence. The algorithm provides recommendations for the best potential treatment according to patients' profiles.
Article
Oncology
Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Mario Pirisi, Piera Federico, Bruno Daniele, Marianna Silletta, Paolo Gallo, Caterina Cocuzza, Maurizio Russello, Giuseppe Cabibbo, Gabriele Rancatore, Silvia Cesario, Gianluca Masi, Luca Marzi, Andrea Mega, Alessandro Granito, Giulia Pieri, Edoardo G. G. Giannini, Rosa Paolillo, Gennaro Gadaleta-Caldarola, Vincenzo Dadduzio, Guido Giordano, Luca Giacomelli, Simonetta Papa, Matteo Renzulli, Marcello Maida, Michele Ghidini, Mauro Borzio, Antonio Facciorusso
Summary: Hepatocellular carcinoma is the fifth most common cancer worldwide. Lenvatinib has proven to be an effective option for treating advanced diseases. Our study showed that patients with nonviral etiologies have longer survival than those with viral etiology, which is important for clinical decision-making.
Editorial Material
Oncology
Luca Giacomelli, Rodolfo Sacco, Simonetta Papa, Brian I. Carr
Editorial Material
Oncology
Stefano Kayali, Elisa Marabotto, Edoardo Giannini
Review
Pharmacology & Pharmacy
Diego Bagnasco, Edoardo Vincenzo Savarino, Mona-Rita Yacoub, Fulvio Braido, Maria Giulia Candeliere, Edoardo Giannini, Giovanni Passalacqua, Elisa Marabotto
Summary: Type 2 inflammation plays a crucial role in various diseases, and drugs originally developed for severe asthma have shown potential in treating eosinophilic esophagitis. Promising results from clinical trials suggest that these drugs may also be used in gastroenterology in the future.
Article
Gastroenterology & Hepatology
David J. Pinato, Takahiro Kaneko, Antonio D'Alessio, Alejandro Forner, Petros Fessas, Beatriz Minguez, Edoardo G. Giannini, Federica Grillo, Alba Diaz, Francesco A. Mauri, Claudia A. M. Fulgenzi, Alessia Dalla Pria, Robert D. Goldin, Giulia Pieri, Pierluigi Toniutto, Claudio Avellini, Maria Corina Plaz Torres, Ayse U. Akarca, Teresa Marafioti, Sherrie Bhoori, Jose Maria Miro, Mark Bower, Norbert Brau, Vincenzo Mazzaferro
Summary: The aim of this study was to evaluate the impact of HIV infection on the functional characteristics of T cell infiltrate in hepatocellular carcinoma (HCC). Results showed that HIV infection was associated with increased immune exhaustion and higher expression of PD-L1 in tumor tissue. Therefore, prospective testing of immunotherapy in HIV-associated HCC is warranted.
Article
Rheumatology
Ylenia Marten Canavesio, Andrea Pasta, Francesco Calabrese, Elisa Alessandri, Maurizio Cutolo, Sabrina Paolino, Carmen Pizzorni, Alberto Sulli, Vincenzo Savarino, Edoardo Giovanni Giannini, Patrizia Zentilin, Giorgia Bodini, Manuele Furnari, Edoardo Savarino, Elisa Marabotto
Summary: This study aims to evaluate the association and prognostic implication between motor esophageal disorders and pulmonary involvement in SSc patients. The study found that the severity of motor esophageal disorders is positively correlated with the severity of pulmonary disease.
RHEUMATOLOGY INTERNATIONAL
(2023)
Review
Medicine, General & Internal
Elisa Pinto, Filippo Pelizzaro, Fabio Farinati, Francesco Paolo Russo
Summary: Hepatocellular carcinoma (HCC) is a common liver malignancy, and angiogenesis plays a crucial role in its development and progression. Deregulated angiogenic pathways have been identified as therapeutic targets in HCC. Locoregional and systemic treatments aim to disrupt tumor blood supply, but this may induce neoangiogenesis and tumor recurrence. Currently available tyrosine kinase inhibitors and monoclonal antibodies primarily target angiogenic pathways for HCC treatment.
MEDICINA-LITHUANIA
(2023)
Article
Oncology
Brian I. I. Carr, Vito Guerra
Summary: Multiple serum parameters were evaluated to determine their relationship with survival in patients with hepatocellular carcinoma. The combination of serum albumin plus GGT levels was found to be the most prognostically useful among the inflammation parameters that were tested.
Article
Medicine, General & Internal
Fatih Ozdemir, Volkan Ince, Sertac Usta, Brian I. I. Carr, Harika G. G. Bag, Ayse Nur Akatli, Aysegul Sagir Kahraman, Sezai Yilmaz
Summary: This study reviewed and compared the prognostic impact and clinicopathologic features of incidental hepatocellular carcinoma (iHCC) patients and hepatocellular carcinoma diagnosed before liver transplantation (pdHCC) patients. The results showed that iHCC patients had better histopathologic features and survival rates with lower tumor recurrence compared to pdHCC patients.
MEDICINA-LITHUANIA
(2023)
Letter
Medicine, General & Internal
Edoardo G. Giannini, Tommaso Testa, Federica Grillo, Luca Mastracci, Serena Arrigo, Piero Cai, Sabrina Paolino, Martina Burlando, Livia Pisciotta, Elena Formisano, Giuseppe Cittadini, Francesco Copello, Sabrina Tuo, Giorgia Bodini
Summary: The establishment of an interdisciplinary IBD center is associated with improved healthcare utilization, including a decrease in hospitalizations per patient/year, a decrease in length of hospitalization, and an increase in patients on biologics.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)